Welcome to our dedicated page for Evolent Health news (Ticker: EVH), a resource for investors and traders seeking the latest updates and insights on Evolent Health stock.
Evolent Health Inc (NYSE: EVH) delivers transformative healthcare solutions through value-based care models and AI-powered technology. This news hub provides investors and healthcare professionals with essential updates on the company developments shaping modern care delivery.
Access authoritative coverage of EVH's strategic initiatives including specialty care management advancements, AI-driven clinical review systems, and partnerships with major health systems. Our curated news collection features earnings reports, regulatory filings, and analysis of operational milestones in oncology, cardiology, and musculoskeletal care management.
Key focus areas include updates on Evolent's proprietary platforms for total cost of care optimization, health plan administration innovations, and value-based payment model expansions. Stay informed about technological integrations like the Machinify Auth AI system that streamline clinical decision-making processes.
Bookmark this page for real-time updates on EVH's progress in aligning financial incentives with patient outcomes. Monitor how their integrated approach to population health management continues to redefine care delivery standards across healthcare networks.
Evolent Health has nominated Richard Jelinek for election to its Board of Directors at the upcoming annual meeting scheduled for June 8, 2023. Jelinek, who is a managing partner at Czech One Capital Partners, has extensive experience in the health care sector, including executive roles at Aetna and CVS Health. His appointment coincides with the departure of current board member David Farner and former Chairman Frank Williams, both set to leave the board in June 2023. Evolent's leadership believes Jelinek's expertise will enhance the board's perspectives and support the company’s mission in value-based specialty care. The board expressed gratitude for the contributions of Farner and Williams, emphasizing the importance of evolving governance.
Evolent Health (NYSE: EVH) announced on March 29, 2023, an agreement with Centene Corporation (NYSE: CNC) to enhance its Technology and Services solution for oncology care. This partnership will extend Evolent's oncology services to Centene’s Medicare Advantage members across the nation, deepening their existing collaboration in the specialty care market. Both companies aim to optimize oncology outcomes while managing costs effectively. Evolent's established platform, backed by scientific advisory boards, focuses on clinical quality and financial accountability, ensuring improved care delivery for patients.
Evolent Health (NYSE: EVH) announced participation in several upcoming investor conferences. Chief Financial Officer John Johnson and Vice President of Investor Relations Seth Frank will represent the company. Details include:
- March 7, 2023: Cowen 43rd Annual Healthcare Conference in Boston at 10:30 a.m. ET.
- March 13, 2023: Annual Jefferies Value-Based Healthcare Summit in Miami Beach (no webcast).
- March 14, 2023: Barclays Global Healthcare Conference in Miami Beach at 3:35 p.m. ET.
Webcast recordings will be available on the investor relations section of Evolent's website. Evolent Health focuses on clinical and administrative solutions that improve health care affordability and accessibility.
Evolent Health (NYSE: EVH) reported Q4 and full-year 2022 financial results, showing significant growth. Q4 revenue reached $382.4 million, up 54.0% year-over-year, while full-year revenue totaled $1.35 billion, a 48.9% increase. Despite revenue growth, the company faced a net loss of $11.3 million for Q4, resulting in a net loss margin of (3.0)%. Total Lives on Platform expanded to 20.6 million. For 2023, Evolent secured new partnerships, including a significant sale expected to generate over $250 million in revenue for 2024. The company anticipates first-quarter revenue between $420 million and $440 million and full-year revenue of approximately $1.92 to $1.96 billion.
Evolent Health, Inc. (NYSE: EVH) has announced that it will release its fourth quarter 2022 financial results on February 22, 2023, after market close. A conference call will follow at 5:00 p.m. Eastern Time. Shareholders and interested parties can listen to the call by dialing 855.940.9467 for domestic calls or 412.317.6034 for international access, referencing the Evolent Health call.
An audio playback will be available on the company's investor relations website for 90 days post-call. Evolent Health is known for delivering clinical and administrative solutions that enhance health care affordability and efficiency.
Evolent Health, Inc. (NYSE: EVH) announced participation in investor conferences featuring CEO Seth Blackley, CFO John Johnson, and VP Seth Frank. Key events include the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 10:30 a.m. ET and the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 4:30 p.m. ET. A live audio webcast will be available on Evolent's Investor Relations website. Evolent Health focuses on improving healthcare delivery through clinical and administrative solutions.
Evolent Health announced its agreement to acquire NIA, a specialty benefit management organization owned by Centene, for $650 million. The acquisition, set to close in mid-2023, is expected to add $85 million in adjusted EBITDA by 2024 and enhance Evolent’s value-based specialty care leadership. The deal diversifies Evolent's revenue base and increases cross-selling opportunities from $16 billion to $50 billion. The NIA acquisition will maintain Evolent's strong balance sheet and is projected to immediately improve cash flow and adjusted EBITDA margins.
FAQ
What is the current stock price of Evolent Health (EVH)?
What is the market cap of Evolent Health (EVH)?
